The role of chemokines in atherosclerosis: Recent evidence from experimental models and population genetics

Current Opinion in Lipidology

Volumn 15, Issue 2, 2004, Pages 145-149

  Bursill, Christina A ^a,b   Channon, Keith M ^a   Greaves, David R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CC chemokine; Coronary artery disease; Fractalkine; Inflammation; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CX3C CHEMOKINE; FRACTALKINE; FRACTALKINE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL MODEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; EXPERIMENTAL MODEL; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; NONHUMAN; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; TRANSGENE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CHEMOKINES; CHEMOKINES, CX3C; GENETICS, POPULATION; HUMANS; MEMBRANE PROTEINS; MICE; MODELS, ANIMAL; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE; RECEPTORS, HIV;

ANIMALIA; MURINAE;

EID: 1842609783     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200404000-00007     Document Type: Review

References (31)

1. Houshmand P, Zlotnik A. Therapeutic applications in the chemokine superfamiry. Curr Opin Chem Biol 2003; 7:457-460.
2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104:503-516.
3. Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler Rep 2001; 3:243-251.
4. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1098; 394:894-897.
5. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103:773-778.
6. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19:1518-1525.
7. Ni W, Egashira K, Kitamoto S, et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001; 103:2096-2101.
8. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106:2700-2706.
9. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106:1523-1529.
10. -/- mice are not protected against atherosclerosis.
11. Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology. From basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24:34-40.
12. Wong BW, Wang D, McManus BM, Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002; 11:332-338. This report demonstrates that fractalkine is expressed on macrophages, foam cells and SMCs.
13. 3CR1 is expressed on human aortic SMCs and that they undergo cell migration toward fractalkine.
14. Chandrasekar B, Mummidi S, Perla RP, et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373:547-558. This detailed study shows that fractalkine expression is stimulated by tumour necrosis factor-α and induces aortic SMC proliferation and adhesion.
15. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-530.
16. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9:61-67. This is the first report to determine the importance of activated platelets in atherosclerosis.
17. Schafer A, Schulz C, Eigenthaler M, et al. Novel role of the membrane bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103:407-412. This recent work shows that fractalkine increases activation and adhesion of platelets.
18. 3CR1/ApoE double knockout mice have reduced atherosclerotic lesion size and macrophage infiltration.
19. 3CR1 in this disease.
20. Lee B, Doranz BJ, Rana S, et al. Influence of the CCR2-V641 polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1098; 72:7450-7458.
21. Ortlepp JR, Vesper K, Mevissen V, et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003; 81:363-367. This recent, larger human population trial provides evidence of an association between the CCR2-V64I allele and CAD.
22. Petrkova J, Cermakova Z, Drabek J, et al. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett 2003; 88:53-55. In this smaller human population trial, an association between the CCR2-V64I allele and increased MI in females younger than 50 years was found.
23. Valdes AM, Wolfe ML, O'Brien EJ, et al. Val64IIe polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol 2002; 22:1924-1928.
24. Gonzalez P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191-195.
25. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158:233-239.
26. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259:344-348.
27. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147:213-225.
28. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999; 96:4581-4585.
29. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97:1925-1928.
30. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89:401-407.
31. 3CR1-M280 is associated with decreased CAD risk independent of I249.